Cable Hill Partners’s Neurocrine Biosciences NBIX Stock Holding History

Cable Hill Partners’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-171	Closed	-$8K	–	856
2016 Q3	$8K	Sell	171 -8	-4%	-$398	0.01%	472
2016 Q2	$9K	Hold	179	–	–	0.01%	389
2016 Q1	$8K	Buy	179 +8	+5%	+$317	0.01%	387
2015 Q4	$10K	Hold	171	–	–	0.01%	349
2015 Q3	$8K	Hold	171	–	–	0.01%	413
2015 Q2	$9K	Hold	171	–	–	0.01%	469
2015 Q1	$7K	Buy	+171	New	+$6.12K	0.01%	507

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Cable Hill Partners's NBIX Position: Q4 2016 in Review

Cable Hill Partners sold out of Neurocrine Biosciences (NBIX) in Q4 2016, closing a stake of 171 shares — an estimated $8K sold.

Cable Hill Partners first reported a position in NBIX in Q1 2015 and held it in 7 quarters. The position peaked at $10K in Q4 2015. 225 funds tracked by Wall St. Rank hold NBIX as of Q4 2016.

Cable Hill Partners reported no remaining Neurocrine Biosciences position as of Q4 2016 after selling out during the quarter.
Cable Hill Partners sold 171 Neurocrine Biosciences shares in Q4 2016, an estimated $8K.
Cable Hill Partners first reported a position in Neurocrine Biosciences in Q1 2015 and held it in 7 quarters.
Cable Hill Partners's Neurocrine Biosciences position peaked at $10K in Q4 2015.
225 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2016.

Based on Cable Hill Partners's 13F filing for Q4 2016, filed 10 Feb 2017.